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Abstract
Background
The evidence to support dressing standards for breast surgery wounds is empiric and
scarce.
Objective
This two-arm randomized clinical trial was designed to assess the effect of dressing wear
time on surgical site infection (SSI) rates, skin colonization and patient perceptions.
Methods
A total of 200 breast cancer patients undergoing breast reconstruction were prospectively
enrolled. Patients were randomly allocated to group I (dressing removed on the first postop-
erative day, n = 100) or group II (dressing removed on the sixth postoperative day, n = 100).
SSIs were defined and classified according to criteria from the Centers for Disease Control
and Prevention. Samples collected before placing the dressing and after 1 day (group I) and
6 days (both groups) were cultured for skin colonization assessments. Patients preferences
and perceptions with regard to safety, comfort and convenience were recorded and
analyzed.
Results
A total of 186 patients completed the follow-up. The global SSI rate was 4.5%. Six patients
in group I and three in group II had SSI (p = 0.497). Before dressing, the groups were similar
with regard to skin colonization. At the sixth day, there was a higher colonization by coagu-
lase-negative staphylococci in group I (p<0.0001). Patients preferred to keep dressing for
six days (p<0.0001), and considered this a safer choice (p<0.05).
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Conclusions
Despite group I had a higher skin colonization by coagulase-negative staphylococci on the
sixth postoperative day, there was no difference in SSI rates. Patients preferred keeping
dressing for six days and considered it a safer choice.
Trial Registration
ClinicalTrials.gov NCT01148823
Background
Owing to its numerous and varied psychosocial benefits, breast reconstruction is currently
considered to be an integral part of breast cancer treatment [1]. However, surgical site infec-
tion (SSI) is a major cause of postoperative morbidity after breast reconstruction. Despite
being considered a clean procedure, breast cancer surgery has been associated with higher SSI
rates than would be expected for other clean surgical procedures [2]. These rates vary widely in
literature, with reported rates of up to 53% [3,4–9].
SSI often leads to longer hospital stay, hospital readmission, reoperation, reconstructive
failure, implant loss, delay of postoperative adjuvant therapies and psychosocial distress [3,10–
12]. Furthermore, SSI can increase the costs associated with the surgery and decrease patient
satisfaction after surgery [13,14]. Thus, interventions to reduce the incidence of SSI are essen-
tial to reduce not only morbidity, but also costs to the patient and the society [11,13–19].
Risk factors for SSIs can be classified into preoperative (patient-related), perioperative (pro-
cedure-related) and postoperative categories [15,20]. Wound management plays a major role
in mitigating SSI risk factors in the postoperative period [15,20–22]. However, literature on
incisional wound management is scarce, with many issues that need to be clarified [22–24].
The global market for wound dressings is growing, as new materials and application tech-
niques are developed [25–27]. However, there is no solid evidence to guide product choice
[28,29] and traditional low-technology gauze-based dressings are commonly used [30–32].
This kind of dressing is widely used in the public health system in Brazil due to its low cost.
There is also no consensus in literature for how long surgical dressings should be worn.
Some authors recommend the early exposure of the wound [22,23,33], whereas others recom-
mend keeping dressings in place for longer periods, until the sutures or drains are removed
[16,24,31].
The Centers for Disease Control and Prevention (CDC) guidelines for the management of
surgical wounds that are primarily closed instruct that patients should keep their wounds dry
and covered with a sterile dressing for 24–48 hours [20]. There are no recommendations
regarding the type of dressing or the length of time that the dressing should be worn after
breast surgery. Thus, decisions are made empirically, based on the surgeon’s personal
experience.
The current standard in the hospital where the present trial was performed is to remove the
dressing 24 hours after breast reconstruction. In a previous study, we found less colonization
by coagulase-negative staphylococci after reduction mammaplasty when dressings were kept
in place longer (for 6 days), without a change in the SSI rate [34]. The results of that trial led us
to hypothesize that keeping the dressing in place longer than the 24–48 hours recommended
by CDC would be beneficial for breast reconstruction patients. However, those findings may
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not apply to breast reconstruction patients, due to several reasons: breast reconstruction is
applied to cancer patients, not to healthy breast hypertrophy women, implants are frequently
used, and the operation time is many times longer than that of reduction mammaplasty, which
may affect the optimal dressing time.
To the best of our knowledge, this is the first randomized trial assessing the time that surgi-
cal dressing should be worn after breast reconstruction. Our primary objective was to assess
the effect of longer surgical dressing wear time on SSI rates. Secondary aims were to assess
skin bacterial colonization and to determine patient preferences and perceptions regarding the
safety, comfort and convenience of surgical dressing wear times.
Methods
Study design, ethics and setting
This is a two-arm parallel group randomized clinical trial. The study protocol has been pub-
lished [35].
This trial was conducted according to the principles expressed in the Declaration of Hel-
sinki. The Institutional Ethics Committee approved the study protocol (Ethics Committee of
the Universidade do Vale do Sapucaı´, 786/07 and 1623/11). Participants were included after
providing written informed consent.
In October 2007, the Ethics Committee approved an initial protocol for a study of patients
undergoing various kinds of clean plastic surgery procedures of the thorax, including breast
reconstruction. However, owing to the great heterogeneity of procedures, we were unable to
attribute any differences in SSI rates, skin colonization or patient perceptions to the length of
time that the dressing was kept in place. Therefore, another randomization in blocks of 40
patients was generated in 2009, with patients stratified by surgical procedure. Only breast
reconstruction patients, recruited after the stratification, were included in the present trial.
Recruitment for the present trial began in June 2009. After 18 months of follow-up, with
the stratified sample, we realized that we could not compare different surgical procedures.
Therefore, the study was split, and the sample size was recalculated for breast reconstruction
surgery specifically. The Ethics Committee approved the breast reconstruction trial in June
2011. Because all procedures remained rigorously the same, the 40 breast reconstruction
patients who had been recruited in 2009 remained in the analysis.
Patients were recruited and followed-up at the Breast Unit of the Plastic Surgery Division of
a university-affiliated hospital, the Hospital das Clı´nicas Samuel Libaˆnio–Universidade do
Vale do Sapucaı´.
Sample size
In our hospital, the average rate of SSI after breast reconstruction was 4% over the last 10
years. A 10% difference in SSI rate was considered clinically relevant [17,34,36]. A one-tailed
hypothesis test for two population proportions was performed (α = 0.05, β = 0.2 or 80%
power) to identify differences in SSI rate between groups I and II. The estimated sample size
was 100 patients per arm.
Eligibility criteria and group assignment
Breast cancer patients aged 18 years and older who were undergoing immediate or delayed
breast reconstruction by any technique were considered eligible for participation. Patients
who smoked heavily, had a body mass index (BMI) above 35kg/m2, were diabetic, who had
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any contraindication for breast reconstruction procedures were excluded, as were patients
whose dressing had gotten wet in the first 24 hours after the operation.
As described previously [35], 200 patients were randomly assigned to group I (n = 100),
with dressings removed on the first postoperative day, or to group II (n = 100), with dressings
removed on the sixth postoperative day.
The allocation was determined by a computer-generated sequence (Bioestat 5.0, Instituto
de Desenvolvimento Sustenta´vel Mamiraua´, Bele´m, PA, Brazil). A sealed, opaque, sequentially
numbered envelope was opened on the first postoperative day to reveal if the patient was
assigned to group I or group II [35].
DFV generated the random allocation sequence. DFV and JVF recruited and selected par-
ticipants, FEMF, IVC and NLLP assigned participants to interventions.
Procedures and interventions
Before admission to the operating unit, all patients were instructed to shower with a liquid
detergent-based 4% chlorhexidine [37]. An alcoholic 0.5% chlorhexidine solution was used for
antisepsis of the surgical site [38]. When an immediate breast reconstruction was performed,
the same antiseptic solution was reapplied to the surgical site after the oncologic operation,
immediately before breast reconstruction.
All participants underwent immediate or delayed breast reconstruction, using flaps and/or
implants. All operations were performed under general anesthesia by the same surgical team.
None of the patients underwent bilateral reconstruction. A drain was used in most patients
and was removed when the discharge was less than 50mL/day.
All patients received 1g of cephalotin administered intravenously at the induction of anes-
thesia and every 6 hours postoperatively, for the first 24 hours. After 24 hours, patients
received 500mg of cephalexin, which was administered orally four times per day, prescribed
for six days.
As described in details in our previously published work [34,35,39], at the end of the opera-
tion, the surgical site was cleaned with sterile physiological saline and swabbed for culture. Sur-
gical wounds were covered with four layers of dry sterile cotton gauze. The wounds were
completely covered, and the gauze layers were fixed in place by a micropore tape. The surgical
team was blinded with regard to the patient allocation into groups.
After 24 hours, the patient group was revealed by opening the sealed envelope with the
patient’s study number. As previously described [34,35,39], patients allocated to group I were
instructed to keep their wounds uncovered and to follow their usual personal hygiene routine.
Patients in group II were instructed not to wet the dressing.
Depending on the breast reconstruction technique used and on patient’s clinical conditions,
patients were discharged from the hospital within 1 to 5 days. To monitor SSI, all patients were
instructed to return for weekly follow-ups for 30 days or at any time after 30 days if they
noticed any signs or symptom of infection, such as localized pain, swelling, redness, wound
disruption, or wound drainage. Patients who received an implant were instructed to return
again after 1 year for follow-up. When a SSI was diagnosed and there were fluids or purulence,
a sample was collected to bacterial culture and antibiogram.
Outcomes measures
The primary outcome variable was SSI. Secondary outcome variables were skin colonization,
as well as patient preferences and perceptions with regard to safety, comfort and convenience
[34,35,39].
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Assessment of SSI
The CDC definitions and classifications of SSI were used. An infection was classified as a
superficial incisional SSI when it involved only skin or subcutaneous tissue, a deep incisional
SSI when it involved deep soft tissues (fascial and muscle layers), or an organ/space SSI when
it involved any other part of the anatomy (organs or spaces) [40].
Infections that appeared to be related to the operation were considered SSIs if they occurred
within 30 days (for surgeries without implants) or within 1 year (for surgeries with implants)
after the operation [40]. A surgeon’s diagnosis of infection was considered an acceptable crite-
rion for an SSI [40].
Skin colonization
The microbiologic methods used were described in detail in our previous publications
[34,35,39]. Samples for skin cultures were obtained immediately before placing the dressing
and immediately after dressing removal. In group I, an additional sample was collected on the
sixth postoperative day. A standard 5 x 10 cm area over the breast surgical wound was swabbed
with two sterile cotton swabs that had been pre-moistened with sterile saline. Each swab was
placed in a sterile container with 1.0 mL of saline and immediately taken to the laboratory.
Standard microbiologic methods were used [41]. As we previously described [34,35,39],
0.2mL aliquots of the first sample were plated on hypertonic manitol (HM) agar, on Sabouraud
agar with chloramphenicol (0.05mg/mL), and on eosin-methylene blue (EMB) agar, selective
for staphylococci, fungi and enterobacteria, respectively. An aliquot of the first sample was also
plated on blood agar, to identify hemolytic colonies. Plates were incubated in an aerobic atmo-
sphere, at 37˚C, for 48 hours (blood agar and EMB agar), 4 days (HM agar) or 7 days (Sabour-
aud agar).
Aliquots of 0.5 mL of the second sample were inoculated into thioglycolate broth and glu-
cose broth. The solutions were incubated aerobically at 37˚C and checked after 72 hours. They
were incubated until they turned positive, at a maximum of seven days. Two blinded labora-
tory technicians processed all samples. After the incubation period, plates and tubes were
examined by a single microbiologist, who was also blinded to patient grouping.
As previously described [34,35,39], culture results were reported as colony forming units
(CFUs) per plate. Whenever the number of CFUs in a plate exceeded 300, it was recorded as
over 300. Staphylococci were identified as coagulase-negative Staphylococcus sp. or S. aureus
by means of the Gram stain, the presence of hemolysis and the coagulase testing. Cultures in
thioglycolate and glucose broths were reported as positive or negative.
Patient perceptions
The preferences and perceptions of patients were assessed at on their 2-week postoperative fol-
low-up visit. Preferences and perceptions were assessed by using a previously published self-
assessment instrument, which scores patients perceptions of safety, comfort and convenience
related to their dressing wear time on a 5-point rating scale. This self-administered instrument
also includes a question about the patient’s preference for wear time (1 day or 6 days)
[34,35,39].
Exit points
As described in the study protocol [35], participation was considered complete after the post-
operative assessment on day 30 (if no implants were used) or after the 12th postoperative
month (if an implant was used) [20]. Other exit points included getting the dressing wet before
Dressing Wear Time after Breast Reconstruction
PLOS ONE | DOI:10.1371/journal.pone.0166356 December 2, 2016 5 / 15
the sixth postoperative day, in group II, requiring withdrawal from the study, and not return-
ing for follow-up assessments.
Blinding
The surgical team, including who applied the dressing, the laboratory technicians who pro-
cessed the samples and the microbiologist were blinded to patient grouping. It was not possible
to blind patients and the surgeon who assessed SSI.
Statistical analysis
Due to the nature of the variables studied, non-parametric statistics were used [42]. The rejec-
tion level for the null hypothesis was fixed at 5% (p 0.05).
The Mann-Whitney U test was used to compare age and BMI of patients groups I and II, as
well as duration of operations. Chi-square tests were applied to compare groups I and II with
regard to the occurrence of SSI, the time of breast reconstruction (immediate/delayed), the
technique of breast reconstruction, the microorganism growth in thioglycolate and glucose
broths, and the patient preference for the dressing wear time (1 day / 6 days), as well as to ver-
ify associations between the occurrence of SSI and the technique of breast reconstruction.
Logistic regressions were applied to detect significant associations between the occurrence of
SSI and variables such as age, BMI and duration of operation.
A Friedman two-way analysis of variance was used to assess differences in the number of
CFUs among the three time points (pre-dressing, first and sixth postoperative days), in group
I. Whenever the difference was significant, multiple comparisons tests were performed to
determine which time points were significantly different [42]. A Wilcoxon signed-rank test
was applied to compare the number of CFUs before dressing and on the sixth postoperative
day, in group II. A Mann-Whitney U test was used to compare skin colonization in groups I
and II before dressing and on the sixth postoperative day. The tests were always applied inde-
pendently for each medium used.
The Fisher Exact Test was used to compare groups I and II with regard to the growth of S.
aureus. The Kolmogorov-Smirnov test was used to compare the two groups regarding patients’
perceptions of safety, comfort and convenience.
Statistical analysis was performed using SPSS (Statistical Package for Social Sciences, Inc.,
Chicago, Ill.) v.18 and Bioestat 5.0 (Instituto de Desenvolvimento Sustenta´vel Mamiraua´,
Bele´m, PA, Brazil).
Results
Patients were recruited between June 2009 and September 2013, and follow-up finished on
October 2014. A total of 186 (93%) patients completed the study. Fig 1 presents the partici-
pants flow diagram [43].
At baseline, groups were matched for age, BMI and duration of operation (Table 1). None
of these variables was associated with a higher incidence of SSI (p = 0.214, p = 0.742 and
p = 0.134, respectively). Groups were also matched for time of breast reconstruction and tech-
nique used (Table 2).
Nine (4.5%) patients developed SSI, six from group I and three from group II. The differ-
ence between groups was not statistically significant (p = 0.497). Six of these patients had
undergone delayed breast reconstruction, and three had undergone immediate reconstruction.
Six patients had tissue expander reconstruction, two patients underwent latissimus dorsi myo-
cutaneous flap reconstruction and one patient had a TRAM flap reconstruction. Groups I and
II each had no association between the breast reconstruction technique used and SSI
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occurrence. However, in an overall analysis including both groups, there was a significant
association with latissimus dorsi flap reconstruction (p = 0.0410, Table 3).
Five patients had deep incisional SSIs, four from group I and one from group II. The other
four patients had superficial incisional SSIs, involving only skin or subcutaneous tissue of the
incision [40]. All five patients with deep incisional SSI had undergone implant reconstruction
and required readmission to the hospital to remove the breast implant. In the other cases, SSI
was successfully treated with oral antibiotics, and none of these patients was readmitted to the
hospital.
Fig 1. CONSORT Flow Diagram [43]
doi:10.1371/journal.pone.0166356.g001
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Time to onset of SSI ranged from 2 to 13 weeks (median ± interquartile range: 3±1.5 weeks)
in group I, and from 2 to 9 weeks (median ± interquartile range: 3±3.5 weeks) in group II.
Group I had significantly higher skin colonization on the sixth postoperative day (Table 4).
Descriptive statistics of CFUs counts and statistical comparisons intragroup and intergroups
are presented in Table 5.
S. aureus was recovered from samples of nine patients (4.5%), seven from group I and two
from group II (p = 0.169). Among the seven patients in group I with S. aureus, four developed
SSI. Neither of the other patients with positive S. aureus cultures, in both groups, developed
SSI. Of the nine cases of SSI in the current study, S. aureus was involved in four (44%), whereas
S. epidermidis was involved in one (11%).
Overall, 163 (81.5%) patients completed the patient perceptions assessment, 82 from group
I and 81 from group II. Table 6 presents patient perceptions of safety, comfort and conve-
nience related to their dressing wear time. Patients preferred to keep dressing on for 6 days
(p<0.0001, Table 7).
Discussion
SSI prevention has gained worldwide attention because of the associated medical costs and
morbidity [11,14,18]. Most hospital readmissions after surgery are due to SSI [1]. With the
recent focus on readmission rates as an indicator of quality of care, to minimize the risk of
Table 1. Demographic and surgical variables of patients in both groups and comparison by Mann-Whitney U test
Group I (n = 100)
Age (years) BMIa (Kg/m2) Duration of operation (minutes)
Range 23–70 19.1–30.8 50–300
Median ± IQRb 48 ± 12 25.8 ± 4.7 100 ± 40
Mean ± SDc 47.8 ± 9.5 25.8 ± 2.9 122.1 ± 62.8
Group II (n = 100)
Range 29–70 20.3–30.0 50–300
Median ± IQRb 50 ± 13 24.9 ± 4.6 90 ± 50
Mean ± SDc 49.3 ± 9.3 25.2 ± 2.9 110.2 ± 57.3
Group I vs. Group II (Mann-Whitney U test)
p = 0.200 p = 0.075 p = 0.094
aBMI: body mass index
bIQR: interquartile range
cSD: standard deviation
doi:10.1371/journal.pone.0166356.t001
Table 2. Time and technique of breast reconstruction and comparison between group I and group II by Chi-square test
Time n
Group I (n = 100) Group II (n = 100) Group I vs. Group II (Chi-square test)
Immediate 58 48 p = 0.157
Delayed 42 52
Technique
Tissue expander / Prosthesis 57 65 p = 0.327
Latissimus dorsi flap 4 6
TRAM flap 14 7
Local or regional flaps 25 22
doi:10.1371/journal.pone.0166356.t002
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patient readmission after surgery is imperative [43]. Although postoperative wound manage-
ment is essential for preventing SSI, few studies have addressed this topic [22,24,34].
Theoretically, the greater the degree of surgical wound contamination is, the higher the risk
of SSI is [18,20]. In the current study, keeping the dressing in place for 6 days led to lower skin
colonization by coagulase-negative staphylococci, but there was no statistical difference
between the groups with regard to the growth of S. aureus. S. epidermidis are the most common
coagulase-negative staphylococci, and have been described as the bacteria most frequently
involved in SSI after breast operations [8]. However, many other authors reported S. aureus as
the most common pathogen causing breast surgery SSI [6,10,12,17,23,30]. Our results support
these findings. S. epidermidis was the microorganism most frequently recovered from our sam-
ples, but was only involved in one case of SSI. S. aureus was involved in four of the nine (44%)
observed cases of SSI, while S. epidermidis was involved in one case (11%). Although there was
an increase in coagulase-negative staphylococci colonization with the shorter dressing time,
the increased colonization rate was not correlated with a significant increase in SSI rates.
The lack of correlation between skin colonization and SSI rates observed in the present trial
may be due to the healing process of properly closed clean incisional wounds. Immediately
after the incision, an inflammatory process begins with the release of inflammatory mediators
that causes vasodilatation. The increased blood flow to the region results in an influx of neu-
trophils and macrophages, which play a role in digesting bacteria. Simultaneously, platelets
adhere to exposed collagen and release the contents of their granules. Platelets and the coagula-
tion cascade are activated by tissue factor, resulting in a fibrin-platelet matrix, which may pre-
vent the invasion of microorganisms into the surgical site [44, 45]. When the wound is
properly closed, the process of reepithelialization occurs quickly, also preventing bacteria from
entering the surgical wound, regardless of whether the dressing is removed after 1 or 6 days.
Table 3. Association between technique of breast reconstruction and SSI occurrence, in groups I and II and overall, by Chi-square test
SSI (n)
Group I (n = 94) Group II (n = 92) Overall (n = 186)
Technique Yes No Yes No Yes No
Tissue expander / Prosthesis 4 49 2 58 6 107
Latissimus dorsi flap 1 3 1 4 2 7
TRAM flap 1 12 - 6 1 18
Local or regional flaps - 24 - 21 - 45
SSI—Yes vs. No (Chi-square test) p = 0.249 p = 0.148 p = 0.041
doi:10.1371/journal.pone.0166356.t003
Table 4. Microorganisms growth in thioglycolate broth and glucose broth and comparison between group I and group II by Chi-square test
n (%)
Thioglycolate broth (+)a Pre dressing (n = 100) Postoperative day 6 (n = 94 / n = 92)
Group I 26 (26.0) 39 (41.5)
Group II 27 (27.0) 21 (22.8)
Group I vs. Group II (Chi-square test) p = 0.873 p = 0.006
Glucose broth (+)a
Group I 28 (28.0) 44 (46.8)
Group II 30 (30.0) 24 (26.1)
Group I vs. Group II (Chi-square test) p = 0.755 p = 0.003
a(+): positive culture
doi:10.1371/journal.pone.0166356.t004
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However, the methods used in this trial did not allow us to characterize the mechanism, and
further investigation is needed.
In contrast to previous studies, we found no associations between age, BMI, or duration of
operation and SSI rates [1,2,7,15,21,36]. Our SSI rate, of 4.5%, was also relatively low. We spec-
ulate that this could be due to the prolonged use of antibiotics. When performing breast
Table 5. Skin colonization results
Number of Colony Forming Units
Group I HMa agar Blood agar EMBb agar Sabouraud agar
Pre dressing (n = 100)
Range 0–300 0–300 0–5 0–26
Median ± IQRc 0 ± 0 0 ± 0 0 ± 0 0 ± 0
Mean ± SDd 4.5 ± 30.1 5.4 ± 30.5 0.1 ± 0.5 0.3 ± 2.6
Postoperative day 1 (n = 100)
Range 0–300 0–300 0–5 0–17
Median ± IQRc 0 ± 0 0 ± 0 0 ± 0 0 ± 0
Mean ± SDd 4.2 ± 30.4 4.5 ± 31.2 0.1 ± 0.5 0.2 ± 1.8
Postoperative day 6 (n = 94)
Range 0–300 0–300 0–300 0–300
Median ± IQRc 4 ± 30.8 2 ± 34.8 0 ± 0 0 ± 0
Mean ± SDd 40.6 ± 85.6 43.7 ± 87.7 7.5 ± 43.8 3.3 ± 30.9
Pre vs. day 1 vs. day 6 (Friedman test) p = 0.000 Pre and day 1 < day 6 p < 0.0001 Pre and day 1 < day 6 p = 0.713 p = 0.976
Group II
Pre dressing (n = 100)
Range 0–86 0–300 0–51 0–0
Median ± IQRc 0 ± 0 0 ± 0 0 ± 0 0 ± 0
Mean ± SDd 3.8 ± 13.9 8.2 ± 35.1 0.5 ± 5.1 0 ± 0
Postoperative day 6 (n = 92)
Range 0–300 0–300 0–0 0–0
Median ± IQRc 0 ± 0 0 ± 0 0 ± 0 0 ± 0
Mean ± SDd 8.9 ± 44.5 11.4 ± 48.6 0 ± 0 0 ± 0
Pre vs. day 6 (Wilcoxon test) p = 0.879 p = 0.811 p = 0.317 -
Group I vs. Group II (Mann-Whitney U test)
Pre dressing p = 0.883 p = 0.875 p = 0.999 p = 0.807
Postoperative day 6 p < 0.000 Group I >Group II p < 0.0001 Group I > Group II p = 0.380 p = 0.616
aHM: hypertonic manitol
bEMB: eosin-methylene blue
cIQR: interquartile range
dSD: standard deviation
doi:10.1371/journal.pone.0166356.t005
Table 6. Perceptions of patients in group I (n = 82) and group II (n = 81) related to their dressing wear time
Safety n (%) Comfort n (%) Convenience n (%)
Group I Group II Group I Group II Group I Group II
Excellent 42 (51) 64 (79) 43 (52) 46 (57) 59 (72) 46 (57)
Very good 23 (28) 13 (16) 24 (29) 20 (25) 20 (24) 20 (25)
Good 17 (21) 4 (5) 15 (18) 15 (18) 3 (4) 15 (18)
Group I vs. Group II (Kolmogorov-Smirnov test) p < 0.05 p > 0.05 p > 0.05
doi:10.1371/journal.pone.0166356.t006
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surgery, if no implants are used, most American surgeons give intravenous cephalosporin pre-
operatively, stopping antibiotics right after surgery [46]. Brazilian breast surgeons do the same.
However, when a reconstructive procedure is performed, particularly when an implant is
placed, plastic surgeons are concerned that SSI will lead to reconstruction failure [2,46].
Indeed, women undergoing breast reconstruction with implants are up to ten times more
likely to develop an SSI than patients undergoing aesthetic implant operations [4]. Thus, in
these cases, plastic surgeons broadly support the prolonged use of antibiotics [2,17].
Two recent papers assessed the use of antibiotics following breast reconstruction, and both
concluded that further studies are needed to clarify this issue [47,48]. In our hospital, it is stan-
dardized the use of cephalosporin for seven days following breast reconstruction, administered
intravenously at the induction of anesthesia and for 24 hours and subsequently administered
orally for additional six days, if no infectious complications occur. Thus, this antibiotic regi-
men was implemented in our trial.
Korol et al., in a systematic review of risk factors associated with SSI among different surgi-
cal procedures, found a time until onset of SSI ranging from 6.2 to 41.4 days post-surgery, with
a median overall time of 17 days. They observed that the time until onset tended to be highest
in orthopedic surgery and transplant operations, probably due to the risk of delayed infection
associated with implants [19]. Our results support these findings, as our overall time until SSI
onset was high (median: 3 weeks, range: 2–13 weeks) and 89% of patients (8/9) who developed
an SSI (89%) had an implant. We also found a significant association between latissimus dorsi
flap reconstruction, which includes an implant, and the occurrence of SSI. However, this asso-
ciation could be due to the small number of latissimus dorsi flap reconstructions performed in
the present study. Of the nine latissimus dorsi flap reconstructions performed, two (22.2%)
resulted in an SSI, which is a high proportion.
In the current evidence-based medicine era, patient-reported outcomes assessment is a key
component of evaluating the success of any procedure. Patient preferences and tolerance must
be considered in these assessments [29, 49]. As we hypothesized in the published study proto-
col [35], the disfiguring characteristic of breast cancer surgical treatment could lead patients to
prefer to keep the dressing in place for a longer period, delaying the moment of seeing their
reconstructed breasts. Indeed, we found that patients significantly preferred having the dress-
ings in place for 6 days and perceived it as a safer choice.
This trial had several limitations, which should be considered when interpreting its results.
This was a single-center study, and all the operations were performed by the same surgical
team. Thus, the specific practice style of the center, such as antibiotics use standards and surgi-
cal team abilities may have influenced the results, limiting their generalizability. Another limi-
tation was the non-inclusion of patients who had a wet dressing in the first 24 hours, requiring
the change of the dressing, because these patients might have been more be prone to SSI
occurrence.
Table 7. Patients’ preferences for dressing wear time and comparison between groups I and II by Chi-
square test
Preference
n (%)
1 Day 6 Days
Group I (n = 82) 68 (82.9) 14 (17.1)
Group II (n = 81) 7 (8.6) 74 (91.4)
Group I vs. Group II (Chi-square test) p < 0.0001
doi:10.1371/journal.pone.0166356.t007
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Conclusions
To date, there are no recommendations for the type of dressing or for the ideal dressing wear
time after breast surgery. The current trial did not demonstrate any significant effect of dress-
ing wear time on SSI rates after breast reconstruction, although keeping the dressing in place
for 6 days led to lower skin colonization by coagulase-negative staphylococci. However,
patients preferred to keep the dressing on for 6 days and considered this a safer choice. There-
fore keeping the dressing in place for a longer time, beyond the 24–48 hours currently recom-
mended, may be beneficial for breast reconstruction patients. Further multi-center studies,
with larger sample sizes, are necessary to reach a conclusive answer regarding dressing wear
time after breast reconstruction.
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